Comparing the patients’ subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires

References

• Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. JCO. 2016;34:557–565.
   PubMed Web of Science ®Google Scholar
• Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197–198.
   PubMed Web of Science ®Google Scholar
• Denis F, Lethrosne C, Pourel N, et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst. 2017;109:9.
   Google Scholar
• Baujat B, Bourhis J, Blanchard P, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010;12:CD002026.
   PubMed Web of Science ®Google Scholar
• Marta GN, Silva V, de Andrade Carvalho H, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110:9–15.
   PubMed Web of Science ®Google Scholar
• Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.
   PubMed Web of Science ®Google Scholar
• Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–136.
   PubMed Web of Science ®Google Scholar
• Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221–1237.
   PubMed Web of Science ®Google Scholar
• Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. JCO. 2008;26:3582–3589.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Rosenthal DI, Weymuller EA, et al. Increasing toxicity in nonoperative head and neck cancer treatment: investigations and interventions. Int J Radiat Oncol Biol Phys. 2007;69:S79–S82.
   PubMed Web of Science ®Google Scholar
• Rathod S, Gupta T, Ghosh-Laskar S, et al. Quality-of-life (QOL) outcomes in patients with head and neck squamous cell carcinoma (HNSCC) treated with intensity-modulated radiation therapy (IMRT) compared to three-dimensional conformal radiotherapy (3D-CRT): evidence from a prospective randomized study. Oral Oncol. 2013;49:634–642.
   PubMed Web of Science ®Google Scholar
• Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981–991.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–181.
   PubMed Web of Science ®Google Scholar
• Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940.
   PubMed Web of Science ®Google Scholar
• Jensen K, Bonde Jensen A, Grau C. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires. Radiother Oncol. 2006;78:298–305.
   PubMed Web of Science ®Google Scholar
• Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;1;142:517–523.
   PubMed Web of Science ®Google Scholar
• Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. JCO. 2014;32:1480–1501.
   PubMed Web of Science ®Google Scholar
• Ojo B, Genden EM, Teng MS, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012;48:923–937.
   PubMed Web of Science ®Google Scholar
• Chera BS, Eisbruch A, Murphy BA, et al. Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. J Natl Cancer Inst. 2014;106:1–4.
   Google Scholar
• Jensen K. Measuring side effects after radiotherapy for pharynx cancer. Acta Oncol. 2007;46:1051–1063.
   PubMed Web of Science ®Google Scholar
• Francis JJ, Johnston M, Robertson C, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25:1229–1245.
   PubMed Web of Science ®Google Scholar
• The National Center for Biomedical Ontology. Medical Dictionary for Regulatory Activities [Internet]. 2018 Jul 6. Available from: https://www.meddra.org/
   Google Scholar
• Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
   Google Scholar
• Bjordal K, Hammerlid E, Ahlner-Elmqvist M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. JCO. 1999;17:1008–1019.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.
   PubMed Web of Science ®Google Scholar
• D’Antonio LL, Zimmerman GJ, Cella DF, et al. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 1996;122:482–487.
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Mendoza TR, Chambers MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923–931.
   PubMed Web of Science ®Google Scholar
• Funk GF, Karnell LH, Christensen AJ, et al. Comprehensive head and neck oncology health status assessment. Head Neck. 2003;25:561–575.
   PubMed Web of Science ®Google Scholar
• Terrell JE, Nanavati KA, Esclamado RM, et al. Head and neck cancer-specific quality of life: instrument validation. Arch Otolaryngol Head Neck Surg. 1997;123:1125–1132.
   PubMed Web of Science ®Google Scholar
• Hassan SJ, Weymuller EA Jr. Assessment of quality of life in head and neck cancer patients. Head Neck. 1993;15:485–496.
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. JCO. 1993;11:570–579.
   PubMed Web of Science ®Google Scholar
• Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Natl Cancer Inst. 2014;106:1–11.
   Google Scholar
• Hay JL, Atkinson TM, Reeve BB, et al. Cognitive interviewing of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res. 2014;23:257–269.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
   Google Scholar
• Sandler KA, Mitchell SA, Basch E, et al. Content validity of anatomic site-specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) item sets for assessment of acute symptomatic toxicities in radiation oncology. Int J Radiat Oncol Biol Phys. 2018;102:44–52.
   PubMed Web of Science ®Google Scholar
• Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–1632.
   PubMed Web of Science ®Google Scholar
• Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clin Cancer Res. 2016;22:1553–1558.
   PubMed Web of Science ®Google Scholar
• Bjordal K, de Graeff A, Fayers PM, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000;36:1796–1807.
   PubMed Web of Science ®Google Scholar
• Basch E, Rogak LJ, Dueck AC. Methods for implementing and reporting Patient-Reported Outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Therap. 2016;38:821–830.
   PubMed Web of Science ®Google Scholar
• LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care – hearing the patient voice at greater volume. Nat Rev Clin Oncol. 2017;14:763–772.
   PubMed Web of Science ®Google Scholar
• Price A, Albarqouni L, Kirkpatrick J, et al. Patient and public involvement in the design of clinical trials: an overview of systematic reviews. J Eval Clin Pract. 2018;24:240–253.
   PubMed Web of Science ®Google Scholar
• Taarnhoj GA, Kennedy F, Absolom K, et al. Comparison of EORTC QLQ-C30 and PRO-CTCAE(TM) questionnaires on six symptom items. J Pain Symp Manage. 2018;56(3):421–429
   PubMed Web of Science ®Google Scholar
• van Leeuwen M, Husson O, Alberti P, et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outc. 2018;16:114.
   PubMed Web of Science ®Google Scholar
• Langendijk JA, Orecchia R, Haustermans K, et al. Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol. 2018;128:9–13.
   PubMed Web of Science ®Google Scholar
• Degboe A, Knight SL, Halling K, et al. Patients’ experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study. J Patient Rep Outcomes. 2017;2:33.
   PubMedGoogle Scholar
• Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018;319:483–494.
   PubMed Web of Science ®Google Scholar
• Staniszewska S, Brett J, Simera I, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ. 2017;358:j3453.
   PubMed Web of Science ®Google Scholar